In this final notice, Takeda states that, in alignment with the US FDA, the NATPARA Special Use Program (SUP) closes on December 31, 2025, and no NATPARA shipments will be sent after that date. The letter follows the previously communicated global manufacturing discontinuation of NATPARA in December 2024. Prescribers are urged to develop alternate treatment plans for enrolled patients, including potential transition to the FDA-approved treatment for adult hypoparathyroidism (the letter links Yorvipath's prescribing information).
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.